Clin Gastroenterol Hepatol. 2010 Sep 24. [Epub ahead of print]
Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM.
Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York.
Abstract
In addition to its effects in the liver, chronic hepatitis C virus (HCV) infection can have serious consequences for other organ systems. Extrahepatic manifestations include mixed cryoglobulinemia (MC) vasculitis, lymphoproliferative disorders, renal disease, insulin resistance, type 2 diabetes, sicca syndrome, rheumatoid arthritis-like polyarthritis, and autoantibody production; reductions in quality of life involve fatigue, depression, and cognitive impairment. MC vasculitis, certain types of lymphoma, insulin resistance, and cognitive function appear to respond to anti-HCV therapy. However, treatments for HCV and other biopsychosocial factors can reduce quality of life and complicate management. HCV treatment has a high overall cost that increases when extrahepatic manifestations are considered. HCV appears to have a role in the pathogenesis of MC vasculitis, certain types of lymphoma, and insulin resistance. Clinicians who treat patients with HCV infections should be aware of potential extrahepatic manifestations and how these can impact and alter management of their patients.
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
PMID: 20870037 [PubMed - as supplied by publisher
Source
No comments:
Post a Comment